Free Trial
NASDAQ:SYNH

Syneos Health (SYNH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$42.97
$42.99
50-Day Range
$42.48
$42.98
52-Week Range
$22.89
$52.23
Volume
7.39 million shs
Average Volume
1.92 million shs
Market Capitalization
$4.46 billion
P/E Ratio
62.29
Dividend Yield
N/A
Price Target
N/A
SYNH stock logo

About Syneos Health Stock (NASDAQ:SYNH)

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.

SYNH Stock News Headlines

Hayward Holdings, Inc. (HAYW)
Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
Biden's Successor: The Radical Threat to YOUR Savings!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
Syneos Health Releases 2024 Health Trends
Syneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEO
SYNH Syneos Health, Inc.
Syneos Health execs in line for huge payouts with $7B buyout
See More Headlines
Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
9/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
NASDAQ:SYNH
Employees
28,768
Year Founded
N/A

Profitability

Net Income
$266.50 million
Pretax Margin
1.53%

Debt

Sales & Book Value

Annual Sales
$5.39 billion
Cash Flow
$6.72 per share
Book Value
$33.96 per share

Miscellaneous

Free Float
103,366,000
Market Cap
$4.46 billion
Optionable
Optionable
Beta
1.58
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


SYNH Stock Analysis - Frequently Asked Questions

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.05. Syneos Health's revenue was up 22.7% compared to the same quarter last year.

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA) and ICON Public (ICLR).

This page (NASDAQ:SYNH) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners